News | September 21, 2008

Early Aggressive Treatment Increases Survival for Many Brain Tumor Patients

September 22, 2008 - Early aggressive treatment with chemotherapy prior to radiotherapy may prolong survival for patients with anaplastic oligodendrogliomas according to new research from the Radiation Therapy Oncology Group (RTOG) presented at ASTRO 2008.

RTOG, an NCI-funded national clinical trials group, is a clinical research component of the American College of Radiology (ACR).

Longer-term results of an RTOG study show that administering chemotherapy prior to radiotherapy increased survival for oligodendroglioma patients. Progression-free survival also improved for those receiving the neoadjuvant chemotherapy, a benefit most evident in those whose tumors have deletions of chromosomes 1p and 19q.

“Our research, while providing some answers for patients with oligodendrogliomas, shows that longer follow-up and genetic profiles will be necessary to provide definitive answers for determining initial treatment strategies,” said Gregory Cairncross, M.D., of the University of Calgary Foothills Medical Centre in Calgary, Canada.

RTOG 9402, a phase III study, enrolled 299 anaplastic oligodendroglioma patients from July 1994 until March 2002 at 104 academic and community facilities in the U.S. and Canada. Patients were randomized to receive either standard radiotherapy alone or four cycles of neoadjuvant chemotherapy using procarbazine, lomustine, and vincristine followed by standard radiotherapy. The unadjusted estimated five-year overall survival rate for all patients entered on the study was slightly better for those who received neoadjuvant chemotherapy (49 vs. 46 percent). The adjusted five-year survival rate is significantly different favoring the experimental arm (hazard ratio = 0.66; 95 percent confidence interval (0.46, 0.95); p value = 0.02). For progression-free survival, the unadjusted estimated five-year rate for all patients entered on the study was significantly better for those who received neoadjuvant chemotherapy (37 vs. 22 percent; p value = 0.003). The adjusted five-year overall progression-free survival was also significantly different favoring the experimental arm (hazard ratio = 0.57; 95 percent confidence interval (0.41, 0.79); p value = 0.02).

Molecular analysis of oligodendrogliomas divides these tumors into two groups – those with deletion of both chromosomes 1p and 19q and those without. RTOG research has shown that patients with the deletions have a better response to treatment and overall survival. RTOG 9402 data reports that patients with the deletion had a median survival of 8.7 years vs. 2.7 years for those without the co-deletion (p

For more information: www.rtog.org, www.acr.org

Related Content

The Aquilion Precision CT system from Canon offers very high resolution imaging, which may aid in cancer detection and improved treatment planning in radiation oncology. #ASTRO2018 #ASTRO #ASTRO18

The Aquilion Precision CT system from Canon offers very high resolution imaging, which may aid in cancer detection and improved treatment planning in radiation oncology. 

News | Computed Tomography (CT) | October 19, 2018
October 19, 2018 – At the 2018 American Society of...
IBA's Proteus system and proton therapy solutions will be discussed at ASTRO 2018. #ASTRO18 #ASTRO #ASTRO2018
News | Proton Therapy | October 19, 2018
October 19, 2018 – IBA (Ion Beam Applications S.A.) is sharing how hospitals can secure performance, investment and t
IBA Dosimetry Enters Interoperability Agreement With Varian for Dolphin Monitoring
News | Radiation Therapy | October 17, 2018
IBA (Ion Beam Applications S.A.) announced it has entered into an agreement with Varian with the goal of validating the...
Boston Scientific Closes Acquisition of Augmenix Inc.
News | Prostate Cancer | October 17, 2018
Boston Scientific Corp. announced the close of its acquisition of Augmenix Inc., developer of the SpaceOAR Hydrogel...
Varian Expands Cancer Care Portfolio With Noona Healthcare Acquisition
News | Patient Engagement | October 15, 2018
Varian announced the acquisition of privately-held software company Noona Healthcare, developer of a cloud-based,...
New Guideline for Prostate Cancer Supports Shortened Radiation Therapy
News | Prostate Cancer | October 12, 2018
Three prominent medical societies issued a new clinical guideline for physicians treating men with early-stage prostate...
Surgery, Radiation Therapy Equally Effective in Treating Oropharyngeal Cancer
News | Radiation Therapy | October 09, 2018
A new study by researchers at UT Southwestern Medical Center found no major long-term differences in the effectiveness...
Videos | Treatment Planning | October 08, 2018
Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System, descri